Creo Medical Group plc provided an update in relation to the multi-year collaboration agreement with Intuitive Surgical Inc. ("Intuitive"), which will now expand the number of sites in the UK and Europe undertaking combined lung cancer diagnostic and microwave ablation procedures. Under the collaboration agreement, certain Creo products will be tested for compatibility with Intuitive's Ion Endoluminal System, and it provides a framework for undertaking joint clinical studies ahead of commercial launch of the MicroBlate Flex device. Accelerated timescale for further Lung Tissue ablation cases across UK and Europe As announced in May 2023, the first in-human use of the Company's MicroBlate Flex device for the microwave ablation of soft tissue lung lesions was successfully completed by Professor Shah at Royal Brompton Hospital, part of Guy's and St Thomas' NHS Foundation Trust.

The initial MicroBlate Flex procedure was undertaken in a clinical study1 which is ongoing. In March 2024, P rofessor Shah and his team announced that they had performed the first ever robotic-guided microwave ablation of lung tissue in the same sitting as a diagnostic procedure2. The collaboration agreement amendment will support the collection of post-market clinical evidence as part of a controlled market release ahead of the next stage in commercialisation of the MicroBlate Flex devices.

To achieve this, Intuitive and Creo have agreed to extend the number of sites in theUK and Europe undertaking robotic-guided microwave ablation procedures for lung cancer. Over the next 12 months, Creo and Intuitive will carefully roll out a controlled clinical pioneer programme across multiple sites in the UK and Europe under which a number of trained Ion users will learn how to simultaneously use Creo's MicroBlate Flex devicefor microwave ablation of cancerous tissue. The first cases from these additional sites are expected to begin before the end of the calendar year, alongside the continuation of the work being undertaken at the Royal Brompton.

As is typical in such a controlled market release, the CROMA system will be loaned at no cost along with the MicroBlate Flex devices to cover the initial cases during the proctoring/mentoring phase before each site enters a commercial phase. A member of the Intuitive or Creo clinical team will be present during procedures as part of an oversight program, to carefully monitor cases during this initial phase.